publications-banner.png

Publications 

Reference Publications

Relevant News Links to Worldwide Problem of Antibiotic Resistant Infection

009.png

WHO Warning Antibiotic Resistant Infections

010.png

WHO Warns 10 Million Deaths From Antibiotic Resistant Infections

011.png

Superbug Crisis Already Here

Current National and Health Security

012.png

Antibiotic Resistant Infection Threat to National Security

013.png

Bill Gates on Antibiotic Resistant Infection Threat

DIBI Technology Publications

Anti-infective- Core to CPI Mission (path to human clinical trials) 

01.png

Iron Sequestrant DIBI, a Potential Alternative for Nares Decolonization of Methicillin-Resistant Staphylococcus aureus, is Anti-infective and Inhibitory for Mupirocin-Resistant Isolates. Allan DS, Parquet MDC, Savage KA, Holbein BE. Antimicrob Agents Chemother 64:e02353-19.

x.png

Antibiotic resistant Acinetobacter baumannii  is susceptible to the novel iron-sequestering anti-infective DIBI in vitro and in experimental pneumonia in mice. Parquet MDC, Savage KA, Allan DS, Ang MTC, Chen W, Logan SM, Holbein BE. Antimicrob Agents Chemother.

03.png

Suppresses Experimental MRSA Infection in Mice and Enhances the Activities of Diverse Antibiotics in vitro. Parquet MDC, Savage KA, Allan DS, Davidson RJ, Holbein BE. Front Microbiol.

Novel Iron-Chelator DIBI Inhibits Staphylococcus aureus Growth

06.png

by chelation on the growth of Candida albicans and Candida vini. Holbein BE, Mira de Orduña R.
FEMS Microbiol Lett.

Effect of trace iron levels and iron withdrawal 

02.png

in the Mouse Model of Intraperitoneal Infection. Harris G, Holbein BE, Zhou H, Xu HH, Chen W.

Infect Immun 87:e00591-19.

Potential Mechanisms of Mucin-Enhanced Acinetobacter baumannii Virulence

08.png

Scott CR, Holbein BE, Lehmann CD. Frontiers in Bioscience, Landmark, 25, 673-682, 2020Antimicrob Agents Chemother.

Iron should be restricted in acute infection

05.png

Ang MTC, Gumbau-Brisa R, Allan DS, McDonald R, Ferguson MJ, Holbein BE, Bierenstiel M. Medchemcomm. 

DIBI, a 3-hydroxypyridin-4-one chelator iron-binding polymer with enhanced antimicrobial activity.

b.png

in antibiotic resistant bacteria with new anti-microbial iron withdrawal agents. Holbein BE, Ang MTC, Allan DS, Chen W, Lehmann C. “Mitigation of Antimicrobial Resistance’’ Springer Nature (invited review, in press)

Exploiting the Achilles’ heel of iron dependence 

Read More

Collaborator-led Complementary studies  (re platform aspects of CPI technology) 

DIBI, a novel 3-hydroxypyridin-4-one chelator iron-binding polymer, inhibits breast cancer cell growth and functions as a chemosensitizer by promoting S-phase DNA damage Greenshields AL, Power Coombs MR, Fernando W, Holbein BE, Hoskin DW. Biometals

Anti-inflammatory effects of a novel iron chelator, DIBI, in experimental sepsis.
Thorburn T, Aali M, Kostek L, LeTourneau-Paci C, Colp P, Zhou J, Holbein B, Hoskin D, Lehmann C. Clin Hemorheol Microcirc.

003.png

Chen J, Zhou J, Kelly M, Holbein BE, Lehmann C. Med Hypotheses. 2017. 

Iron chelation for the treatment of uveitis.

006.png

Lehmann C, Islam S, Jarosch S, Zhou J, Hoskin D, Greenshields A, Al-Banna N, Sharawy N, Sczcesniak A, Kelly M, Wafa K, Cheliak W, Holbein B.
Mediators Inflamm. 2015.

The utility of iron chelators in the management of inflammatory disorders.

004.png

of iron chelation in experimental sepsis.
Islam S, Jarosch S, Zhou J, Parquet Mdel C, Toguri JT, Colp P, Holbein BE, Lehmann C. J Surg Res.2016.  

Anti-inflammatory and anti-bacterial effects 

007.png

Hagn G, Westhofen R, Burkovskiy I, Holbein B, Zhou J, Lehmann C. Pharmacology. 2019. 

Iron Chelation as Novel Treatment for Interstitial Cystitis.

005.png

by chelation on the growth of human and murine mammary carcinoma and fibrosarcoma cells.
Power Coombs MR, Grant T, Greenshields AL, Arsenault DJ, Holbein BE, Hoskin DW. Exp Mol Pathol. 2015. 

Inhibitory effect of iron withdrawal 

008.png

to iron chelators in polybacterial abdominal sepsis. Dickson K, Liu S, Zhou J, Langille M, Holbein BE, Lehmann C.
Med Hypotheses. 2018. 

Selective sensitivity of the gut microbiome